InsiderTrades

Form 4 for AMGN Amgen

Accepted 2022-04-29 00:00:00 ET · period of report 2022-04-27 · accession 0001127602-22-012761 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2022-04-29 2022-04-27 AMGN Grygiel Nancy A. SVP, CCO F - Tax $249.87 -60 14.3K -0.4% -$15.0K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-04-27 F D 60 $249.87 14,329 D — — (F1) These shares include the following RSUs granted under the Company's equity plans: 452 RSUs which will vest in one installment on 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 536 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.